Cullinan Management's Zipalertinib Shows Promise in NSCLC, Bolstering Stock Rating
Key Insights
Cullinan Management (search)'s zipalertinib met its primary endpoint in a Phase 2b trial for non-small cell lung cancer (search) (NSCLC (search)), demonstrating a promising overall response rate.
The success of the REZILIENT1 study and a strategic partnership with Taiho Pharmaceutical (search) have led to an increased 'Buy' rating from analysts.
Zipalertinib's potential launch in the U.S. market is projected to generate significant sales, with estimates reaching $397 million by 2031.
Cullinan Management (search) (CGEM) has received an upgraded 'Buy' rating from analysts following the positive results of its Phase 2b REZILIENT1 trial for zipalertinib in previously treated non-small cell lung cancer (search) (NSCLC (search)) patients. The trial's success, coupled with a strategic partnership with Taiho Pharmaceutical (search), has bolstered confidence in the company's future prospects.
The pivotal Phase 2b REZILIENT1 study evaluated zipalertinib in NSCLC (search) patients with specific genetic mutations. The trial met its primary endpoint, demonstrating a promising overall response rate (ORR). Safety data from the trial aligned with previous presentations, further supporting the drug's potential. These positive outcomes pave the way for regulatory submission, planned for the second half of 2025, and presentation at a medical meeting in mid-2025.
Edward White, an analyst from H.C. Wainwright, reiterated the 'Buy' rating on Cullinan Management (search), raising the price target to $33.00. Andrew Berens, an analyst from Leerink Partners, also assigned a 'Buy' rating with a price target of $29.00. Berens cited the increased probability of success for the NSCLC (search) indication, raising it from 70% to 85%, as a key factor in the price target revision.
The partnership with Taiho Pharmaceutical (search) enhances Cullinan's capabilities in clinical development and commercialization. The agreement allows for significant regulatory milestone payments and an equal share of future profits. The anticipated launch of zipalertinib in the U.S. market is projected to generate substantial sales, growing from $41 million in 2026 to $397 million by 2031.
Ongoing Clinical Trials
In addition to the REZILIENT1 trial, Cullinan is actively enrolling patients in the REZILIENT3 Phase 3 study, further solidifying the potential for future advancements. The company also has ongoing trials and upcoming data for other pipeline candidates, such as CLN-978 and CLN-619, in various cancer indications, contributing to its overall growth prospects.
Analyst Sentiment
While corporate insider sentiment on the stock is currently negative, with an increase in insiders selling shares, analysts remain optimistic about Cullinan's future. The positive Phase 2b results and strategic partnerships have instilled confidence in the company's ability to deliver innovative cancer therapies.